Leigh disease

Leigh disease, also known as subacute necrotizing encephalomyelopathy, is a rare inherited disorder that affects the central nervous system. The onset is typically between three months and two years of age, although late-onset forms can occur in adolescence or adulthood. The disease is characterized by the progressive loss of mental and movement abilities (psychomotor regression). Early symptoms may include poor sucking ability, loss of head control, and hypotonia (low muscle tone). As the disease progresses, children may experience seizures, movement disorders such as dystonia (involuntary muscle contractions), ataxia (lack of voluntary coordination), and difficulties with breathing and swallowing.

The diagnosis of Leigh disease is based on clinical symptoms, characteristic findings on magnetic resonance imaging (MRI) of the brain, and genetic testing. MRI scans typically reveal symmetrical lesions in the basal ganglia, brainstem, and cerebellum, which represent areas of tissue death (necrosis) and are a hallmark of the condition. Laboratory tests may also show high levels of lactate in the blood and cerebrospinal fluid, indicating a problem with energy metabolism. The prognosis is generally poor, with a rapid decline leading to significant disability and often death within a few years, usually due to respiratory failure.

Leigh disease is the most common clinical presentation of a mitochondrial disease in childhood. Mitochondria are organelles within cells responsible for generating over 90% of the body's energy in the form of adenosine triphosphate (ATP). When this process, known as oxidative phosphorylation, is defective, cells with high energy demands—particularly those in the brain, nerves, and muscles—are the first to be affected.

The genetic basis of Leigh disease is exceptionally complex. It can be caused by mutations in more than 75 different genes. These genes can be located either in the nuclear DNA (nDNA), inherited from both parents, or in the mitochondrial DNA (mtDNA), which is inherited exclusively from the mother. This genetic heterogeneity explains the variability in symptoms and severity among individuals and makes genetic diagnosis challenging. The specific gene mutation determines the exact biochemical defect in the mitochondrial respiratory chain, the series of protein complexes responsible for energy production.

For patients and their families, a diagnosis of Leigh disease is devastating. There is currently no cure, and treatment is primarily supportive and symptomatic. Management focuses on alleviating symptoms and improving quality of life. This may include anticonvulsant medications for seizures, physical therapy to manage motor difficulties, and nutritional support, sometimes involving a feeding tube. Certain vitamin and co-factor cocktails, such as thiamine (vitamin B1) or coenzyme Q10, may be prescribed to support mitochondrial function, though their effectiveness varies depending on the underlying genetic cause.

The complexity of Leigh disease highlights the significant challenges in treating mitochondrial disorders. Research is focused on understanding the fundamental mechanisms of mitochondrial energy production and developing targeted therapies. Potential future treatments being explored include gene therapy to correct the underlying genetic defect, strategies to bypass the defective parts of the respiratory chain, and the development of drugs that can enhance mitochondrial function or protect cells from damage. These efforts offer hope for improving outcomes for this severe and life-limiting condition.